Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Jabbari, Neda ^a   Reavis, Ashley N ^a   McDonald, John F ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

EMT; MET; Metastasis; MicroRNAs; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MICRORNA; MIRN141 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; MIRN429 MICRORNA, HUMAN; TUMOR MARKER;

CELL SHAPE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENETICS; HUMAN; IC50; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; INHIBITORY CONCENTRATION 50; MICRORNAS; OVARIAN NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84892588866     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-12     Document Type: Article

References (32)

1. Cancer statistics, 2011. Siegel R, Ward E, Brawley O, Jemal A, CA Cancer J Clin 2011 61 212 236 10.3322/caac.20121 21685461
2. Diagnosis and management of peritoneal metastases from ovarian cancer. Halkia E, Spiliotis J, Sugarbaker P, Gastroenterol Res Pract 2012 2012 541842 22888339
3. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Huber MA, Kraut N, Beug H, Curr Opin Cell Biol 2005 17 548 558 10.1016/j.ceb.2005.08.001 16098727 (Pubitemid 41267170)
4. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA, J Clin Invest 2009 119 1438 1449 10.1172/JCI38019 19487820
5. To differentiate or not-routes towards metastasis. Brabletz T, Nat Rev Cancer 2012 12 425 436 10.1038/nrc3265 22576165
6. Mesenchymal to epithelial transition in development and disease. Chaffer CL, Thompson EW, Williams ED, Cells Tissues Organs 2007 185 7 19 10.1159/000101298 17587803 (Pubitemid 46956838)
7. Cancer stemness and metastasis: therapeutic consequences and perspectives. Monteiro J, Fodde R, Eur J Cancer 2010 46 1198 1203 10.1016/j.ejca.2010.02.030 20303259
8. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF, Gyn Onc 2011 121 200 205 10.1016/j.ygyno.2010.12.339
9. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ, Nat Cell Biol 2008 10 593 601 10.1038/ncb1722 18376396 (Pubitemid 351627379)
10. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Park S-M, Gaur AB, Lengyel E, Peter ME, Genes Dev 2008 22 894 907 10.1101/gad.1640608 18381893 (Pubitemid 351482843)
11. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Carpenter A, Jones T, Lamprecht M, Clarke C, Kang I, Friman O, Guertin D, Chang J, Lindquist R, Moffat J, et al. Gen Biol 2006 7 100 10.1186/gb-2006-7-10-r100 (Pubitemid 46453508)
12. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A, J Clin Invest 1990 86 851 855 10.1172/JCI114784 2394835 (Pubitemid 20327375)
13. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Fogh J, Fogh JM, Orfeo T, J Natl Cancer Inst 1977 59 221 226 327080 (Pubitemid 8144854)
14. Biomarkers for epithelial-mesenchymal transitions. Zeisberg M, Neilson EG, J Clin Invest 2009 119 1429 1437 10.1172/JCI36183 19487819
15. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
16. Cadherins: a molecular family important in selective cell-cell adhesion. Takeichi M, Annu Rev Biochem 1990 59 237 252 10.1146/annurev.bi.59.070190.001321 2197976
17. Prediction of mammalian microrna targets. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB, Cell 2003 115 787 798 10.1016/S0092-8674(03)01018-3 14697198 (Pubitemid 38058492)
18. The microRNA.org resource: targets and expression. Betel D, Wilson M, Gabow A, Marks DS, Sander C, Nuc Acids Res 2008 36 149 D153
19. miRDB: A microRNA target prediction and functional annotation database with a wiki interface. Wang X, RNA 2008 14 1012 1017 10.1261/rna.965408 18426918 (Pubitemid 351717482)
20. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Lewis BP, Burge CB, Bartel DP, Cell 2005 120 15 20 10.1016/j.cell.2004.12.035 15652477 (Pubitemid 40094598)
21. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W, Can Res 2009 69 5820 5828 10.1158/0008-5472.CAN-08-2819
22. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al. Clin Cancer Res 2009 15 5060 5072 10.1158/1078-0432.CCR-08-2245 19671845
23. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Shah A, Summy J, Zhang J, Park S, Parikh N, Gallick G, Ann of Surg Oncol 2007 14 3629 3637 10.1245/s10434-007-9583-5 (Pubitemid 350160137)
24. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. Haslehurst A, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al. BMC Cancer 2012 12 91 10.1186/1471-2407-12-91 22429801
25. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al. Eur J Can 2013 49 520 530 10.1016/j.ejca.2012.06.026
26. Metastasis: a question of life or death. Mehlen P, Puisieux A, Nat Rev Cancer 2006 6 449 458 10.1038/nrc1886 16723991
27. Metastatic cancer cell. Bacac M, Stamenkovic I, Annu Rev Path Mechs Dis 2008 3 221 247 10.1146/annurev.pathmechdis.3.121806.151523 (Pubitemid 351488281)
28. SEER cancer statistics review, 1975-2010. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, [ http://seer.cancer.gov/csr/1975-2010/ ]
29. Epithelial-mesenchymal transitions in tumour progression. Thiery JP, Nat Rev Cancer 2002 2 442 454 10.1038/nrc822 12189386
30. Epithelial-mesenchymal transition in ovarian cancer. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M, Cancer Lett 2010 291 59 66 10.1016/j.canlet.2009.09.017 19880243
31. Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis. Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF, J Ovar Res 2013 6 49 10.1186/1757-2215-6-49
32. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Xu H, Hui KM, Can Gene Ther 2012 19 723 730 10.1038/cgt.2012.58